F. Morgan Gasior
Sure. Well, the loan growth in the quarter was actually about what we expected and was our second best quarter of the year and actually was a pretty respectable increase in origination activity, if you look year-over-year. In terms of payoffs, we had a larger amount of payoffs in the multi-family portfolio. One of our customers sold their entire portfolio during the quarter and paid everything off. So that was probably the biggest negative variance to loan growth, almost exactly. We were hoping to get to $1.175 billion, and that was almost the entire difference. We also had a higher than usual scheduled amortization in the equipment finance portfolio, particularly government because that's the fourth quarter of the government's fiscal year. It's typically a busy time for us. So that was a contributing factor as well. But we felt good generally about originations in the third quarter. It just wasn't enough to overcome the – almost doubling of the payoffs and the real estate portfolio for the third quarter. Going into fourth quarter, we like the pipelines going into fourth quarter pretty much across the Board. We were hoping to get to $1.175 billion at the end of third quarter, which would set up hopefully somewhere between $1.2 billion and $1.25 billion at the end of the year. But given the lower starting point, our goal is just to get to $1.2 billion. As you saw during the quarter, we had growth in the commercial and industrial portfolio that has continued here into the fourth quarter. And we have reasonably good pipelines going into the fourth quarter and even into 2023, particularly in the healthcare portfolio and the commercial finance portfolio. We're even seeing some pick-up in activity in the lessor finance portfolio with some new opportunities. Probably what's most noteworthy is we're seeing greater draw activity in the healthcare portfolio that is also some higher coupon average yield credits. So all things considered, we feel fairly positive about the pipelines in the C&I portfolio for 2022 fourth quarter and even going into next year. As market liquidity ebbs a bit and the inflationary environment continues also in the winter, the healthcare credits tend to be more active to begin with. So all those I think are positive trends for greater line utilization, particularly in the healthcare portfolio for fourth quarter and into 2023. And on top of that, as I said, we have a reasonable pipeline for new originations, which will expand commitments. In the equipment finance portfolio, fourth quarter is typically one of our stronger quarters, and we have a pretty good pipeline going into fourth quarter. We expect funding activity to ramp up rather considerably here in November, and the first couple weeks of December before it tails off. So again, we'll see – we have a somewhat higher than average scheduled amortization because fourth quarter is usually the strong quarter historically. But if we can do somewhere in the $60 million range for equipment finance, we'll get some growth out of that portfolio. And if we can do a little bit better than that, if a couple of the larger credits actually fund this quarter, then we'll get a little more meaningful growth out of the equipment finance portfolio. And then real estate has a good pipeline going into fourth quarter. We've seen a couple of nice larger credits come in, lower risk, people looking for a very good rate and term deal. So all-in-all, we see it's feasible to get to $1.25 billion for the fourth quarter of 2022. A number of factors have to drop into place, but we believe it's feasible. If we come a little short or go a little over, I think that's a reasonable range. But our primary goal here is to put as much aboard in the fourth quarter to set up 2023 to be in the strongest possible position, and particularly so in our commercial finance side then followed by equipment finance because that sets up a higher coupon environment and a higher interest income environment for 2023.